Bacterial infections:

Indications for: VABOMERE

Susceptible complicated urinary tract infections (cUTI) including pyelonephritis.

Adult Dosage:

Give by IV infusion over 3hrs. ≥18yrs (eGFR ≥50mL/min/1.73m2): 4g every 8hrs. Renal impairment (eGFR 30–49mL/min/1.73m2): 2g every 8hrs; (eGFR 15–29mL/min/1.73m2): 2g every 12hrs; (eGFR <15mL/min/1.73m2): 1g every 12hrs. Give after hemodialysis session. All: treat for up to 14 days.

Children Dosage:

<18yrs: not established.

VABOMERE Warnings/Precautions:

Previous hypersensitivity to penicillins, cephalosporins, other beta-lactams, or other allergens. Discontinue immediately if allergic reaction occurs. CNS disorders (eg, brain lesions, history of seizures). Bacterial meningitis. Renal impairment (thrombocytopenia possible). Reevaluate dose if focal tremors, myoclonus, or seizures occur. Discontinue if C. difficile-associated diarrhea suspected or confirmed. Pregnancy. Nursing mothers.

VABOMERE Classification:

Carbapenem + beta-lactamase inhibitor.

VABOMERE Interactions:

Concomitant valproic acid or divalproex sodium: not recommended; if use necessary, consider supplemental anticonvulsant. Potentiated by probenecid: not recommended.

Adverse Reactions:

Headache, phlebitis/infusion site reactions, diarrhea; serious hypersensitivity reactions, C. difficile-associated diarrhea, possible neuromotor impairment (eg, seizures, delirium, paresthesias), superinfection.

Generic Drug Availability:


How Supplied:

Single-dose vials—6